Carcinoembryonic antigen-related cell adhesion molecule 1 in cancer: Blessing or curse?
CD66a
CEACAM1
cancer
inflammation
tumorigenicity
tumour microenvironment
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
03
09
2024
accepted:
04
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
aheadofprint
Résumé
The Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1, also CD66a), a transmembrane glycoprotein of the immunoglobulin superfamily, is a pivotal mediator of various physiological and pathological processes, including oncologic disorders. However, its precise role in tumorigenicity is contradictory discussed by several clinical studies. This review aims to elucidate the clinical significance of CEACAM1 in different cancer entities focusing on tumour formation, progression and metastasis as well as on CEACAM1-mediated treatment resistance. Furthermore, we discuss the contribution of CEACAM1 to cancer immunity and modulation of the inflammatory microenvironment and finally provide a comprehensive review of treatment regimens targeting this molecule.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14337Subventions
Organisme : Open Access Publication Fund of the University of Würzburg
Organisme : Cancer Research Advancement Foundation
Organisme : Walter Schulz Foundation
Informations de copyright
© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Svenberg T, Hammarstrom S, Zeromski J. Immunofluorescence studies on the occurrence and localization of the CEA‐related biliary glycoprotein I (BGP I) in normal human gastrointestinal tissues. Clin Exp Immunol. 1979;36(3):436‐441.
Kim WM, Huang YH, Gandhi A, Blumberg RS. CEACAM1 structure and function in immunity and its therapeutic implications. Semin Immunol. 2019;42:101296.
Rueckschloss U, Kuerten S, Ergun S. The role of CEA‐related cell adhesion molecule‐1 (CEACAM1) in vascular homeostasis. Histochem Cell Biol. 2016;146(6):657‐671.
Dankner M, Gray‐Owen SD, Huang YH, Blumberg RS, Beauchemin N. CEACAM1 as a multi‐purpose target for cancer immunotherapy. Onco Targets Ther. 2017;6(7):e1328336.
Gray‐Owen SD, Blumberg RS. CEACAM1: contact‐dependent control of immunity. Nat Rev Immunol. 2006;6(6):433‐446.
Hu W, Bagramyan K, Bhatticharya S, et al. Phosphorylation of human CEACAM1‐LF by PKA and GSK3beta promotes its interaction with beta‐catenin. J Biol Chem. 2021;297(5):101305.
Muller MM, Klaile E, Vorontsova O, Singer BB, Obrink B. Homophilic adhesion and CEACAM1‐S regulate dimerization of CEACAM1‐L and recruitment of SHP‐2 and c‐Src. J Cell Biol. 2009;187(4):569‐581.
Lobo EO, Zhang Z, Shively JE. Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19‐mediated adhesion of B cells in a PI3K‐dependent manner. J Leukoc Biol. 2009;86(2):205‐218.
Behrens IK, Busch B, Ishikawa‐Ankerhold H, et al. The HopQ‐CEACAM interaction controls CagA translocation, phosphorylation, and phagocytosis of Helicobacter pylori in neutrophils. MBio. 2020;11(1):e03256‐19.
Catton EA, Bonsor DA, Herrera C, et al. Human CEACAM1 is targeted by a streptococcus pyogenes adhesin implicated in puerperal sepsis pathogenesis. Nat Commun. 2023;14(1):2275.
Nguyen QA, Schmitt L, Mejias‐Luque R, Gerhard M. Effects of Helicobacter pylori adhesin HopQ binding to CEACAM receptors in the human stomach. Front Immunol. 2023;14:1113478.
Beauchemin N, Draber P, Dveksler G, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res. 1999;252(2):243‐249.
Belcher Dufrisne M, Swope N, Kieber M, et al. Human CEACAM1 N‐domain dimerization is independent from glycan modifications. Structure. 2022;30(5):658‐670 e655.
Zhuo Y, Yang JY, Moremen KW, Prestegard JH. Glycosylation alters dimerization properties of a cell‐surface Signaling protein, carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1). J Biol Chem. 2016;291(38):20085‐20095.
Kammerer R, Hahn S, Singer BB, Luo JS, von Kleist S. Biliary glycoprotein (CD66a), a cell adhesion molecule of the immunoglobulin superfamily, on human lymphocytes: structure, expression and involvement in T cell activation. Eur J Immunol. 1998;28(11):3664‐3674.
Stern N, Markel G, Arnon TI, et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA‐related cell adhesion molecule 1. J Immunol. 2005;174(11):6692‐6701.
Oikawa S, Kuroki M, Matsuoka Y, Kosaki G, Nakazato H. Homotypic and heterotypic Ca(++)‐independent cell adhesion activities of biliary glycoprotein, a member of carcinoembryonic antigen family, expressed on CHO cell surface. Biochem Biophys Res Commun. 1992;186(2):881‐887.
Singer BB, Opp L, Heinrich A, et al. Soluble CEACAM8 interacts with CEACAM1 inhibiting TLR2‐triggered immune responses. PLoS One. 2014;9(4):e94106.
Poy MN, Ruch RJ, Fernstrom MA, Okabayashi Y, Najjar SM. Shc and CEACAM1 interact to regulate the mitogenic action of insulin. J Biol Chem. 2002;277(2):1076‐1084.
Sundberg U, Obrink B. CEACAM1 isoforms with different cytoplasmic domains show different localization, organization and adhesive properties in polarized epithelial cells. J Cell Sci. 2002;115(Pt 6):1273‐1284.
Edlund M, Gaardsvoll H, Bock E, Obrink B. Different isoforms and stock‐specific variants of the cell adhesion molecule C‐CAM (cell‐CAM 105) in rat liver. Eur J Biochem. 1993;213(3):1109‐1116.
Markel G, Achdout H, Katz G, et al. Biological function of the soluble CEACAM1 protein and implications in TAP2‐deficient patients. Eur J Immunol. 2004;34(8):2138‐2148.
Neumaier M, Paululat S, Chan A, Matthaes P, Wagener C. Biliary glycoprotein, a potential human cell adhesion molecule, is down‐regulated in colorectal carcinomas. Proc Natl Acad Sci USA. 1993;90(22):10744‐10748.
Leung N, Turbide C, Olson M, Marcus V, Jothy S, Beauchemin N. Deletion of the carcinoembryonic antigen‐related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene. 2006;25(40):5527‐5536.
Wegwitz F, Lenfert E, Gerstel D, et al. CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo. Oncotarget. 2016;7(39):63730‐63746.
Abou‐Rjaily GA, Lee SJ, May D, et al. CEACAM1 modulates epidermal growth factor receptor–mediated cell proliferation. J Clin Invest. 2004;114(7):944‐952.
Singer BB, Scheffrahn I, Kammerer R, Suttorp N, Ergun S, Slevogt H. Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS One. 2010;5(1):e8747.
Xu J, Liu B, Ma S, et al. Characterizing the tumor suppressor role of CEACAM1 in multiple myeloma. Cell Physiol Biochem. 2018;45(4):1631‐1640.
Han ZM, Huang HM, Sun YW. Effect of CEACAM‐1 knockdown in human colorectal cancer cells. Oncol Lett. 2018;16(2):1622‐1626.
Ortenberg R, Galore‐Haskel G, Greenberg I, et al. CEACAM1 promotes melanoma cell growth through Sox‐2. Neoplasia. 2014;16(5):451‐460.
Ebrahimnejad A, Streichert T, Nollau P, et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol. 2004;165(5):1781‐1787.
Ieda J, Yokoyama S, Tamura K, et al. Re‐expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. Int J Cancer. 2011;129(6):1351‐1361.
Liu J, Di G, Wu CT, Hu X, Duan H. CEACAM1 inhibits cell‐matrix adhesion and promotes cell migration through regulating the expression of N‐cadherin. Biochem Biophys Res Commun. 2013;430(2):598‐603.
Liu W, Wei W, Winer D, et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene. 2007;26(19):2747‐2758.
Arabzadeh A, Beauchemin N. Stromal CEACAM1 expression regulates colorectal cancer metastasis. Onco Targets Ther. 2012;1(7):1205‐1207.
Yamaguchi S, Yokoyama S, Ueno M, et al. CEACAM1 is associated with recurrence after hepatectomy for colorectal liver metastasis. J Surg Res. 2017;220:353‐362.
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31‐46.
Singer BB, Klaile E, Scheffrahn I, et al. CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand‐induced apoptosis in granulocytes. Eur J Immunol. 2005;35(6):1949‐1959.
Yu Q, Chow EM, Wong H, et al. CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3‐kinase‐ and AKT‐dependent pathway. J Biol Chem. 2006;281(51):39179‐39193.
Kilic N, Oliveira‐Ferrer L, Wurmbach JH, et al. Pro‐angiogenic signaling by the endothelial presence of CEACAM1. J Biol Chem. 2005;280(3):2361‐2369.
Yamamoto N, Yokoyama S, Ieda J, et al. CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5‐fluorouracil. Cancer Chemother Pharmacol. 2015;75(2):421‐430.
Khalaji A, Haddad S, Yazdani Y, Moslemi M, Alizadeh L, Baradaran B. A bioinformatics‐based study on the cisplatin‐resistant lung cancer cells; what are the orchestrators of this phenom? Gene. 2022;834:146668.
Dong J, Zhang Y, Wang B, et al. Abstract 1867: pre‐clinical characterization of anti‐CEACAM1 antibod. Cancer Res. 2023;83:1867.
Nittka S, Bohm C, Zentgraf H, Neumaier M. The CEACAM1‐mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1. Oncogene. 2008;27(26):3721‐3728.
Nittka S, Gunther J, Ebisch C, Erbersdobler A, Neumaier M. The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis. Oncogene. 2004;23(58):9306‐9313.
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229‐263.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759‐767.
Song JH, Cao Z, Yoon JH, et al. Genetic alterations and expression pattern of CEACAM1 in colorectal adenomas and cancers. Pathol Oncol Res. 2011;17(1):67‐74.
Nollau P, Scheller H, Kona‐Horstmann M, et al. Expression of CD66a (human C‐CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. Cancer Res. 1997;57(12):2354‐2357.
Kang WY, Chen WT, Wu MT, Chai CY. The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int J Color Dis. 2007;22(8):869‐874.
Gaur S, Shively JE, Yen Y, Gaur RK. Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms. Mol Cancer. 2008;7:46.
Yang C, He P, Liu Y, et al. Down‐regulation of CEACAM1 in breast cancer. Acta Biochim Biophys Sin Shanghai. 2015;47(10):788‐794.
Yang C, He P, Liu Y, et al. Assay of serum CEACAM1 as a potential biomarker for breast cancer. Clin Chim Acta. 2015;450:277‐281.
Ohwada A, Takahashi H, Nagaoka I, Kira S. Biliary glycoprotein mRNA expression is increased in primary lung cancer, especially in squamous cell carcinoma. Am J Respir Cell Mol Biol. 1994;11(2):214‐220.
Laack E, Nikbakht H, Peters A, et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol. 2002;20(21):4279‐4284.
Sienel W, Dango S, Woelfle U, et al. Elevated expression of carcinoembryonic antigen‐related cell adhesion molecule 1 promotes progression of non‐small cell lung cancer. Clin Cancer Res. 2003;9(6):2260‐2266.
Dango S, Sienel W, Schreiber M, et al. Elevated expression of carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM‐1) is associated with increased angiogenic potential in non‐small‐cell lung cancer. Lung Cancer. 2008;60(3):426‐433.
Thom I, Schult‐Kronefeld O, Burkholder I, et al. Expression of CEACAM‐1 in pulmonary adenocarcinomas and their metastases. Anticancer Res. 2009;29(1):249‐254.
Zhou MQ, Du Y, Liu YW, et al. Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen‐related cell adhesion molecule 1 in non‐small‐cell lung cancer. BMC Cancer. 2013;13:359.
Nolen BM, Lomakin A, Marrangoni A, Velikokhatnaya L, Prosser D, Lokshin AE. Urinary protein biomarkers in the early detection of lung cancer. Cancer Prev Res (Phila). 2015;8(2):111‐119.
Davey MG, Miller N, McInerney NM. A review of epidemiology and cancer biology of malignant melanoma. Cureus. 2021;13(5):e15087.
Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20(10):2530‐2536.
Thies A, Berlin A, Brunner G, et al. Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases. Cancer Lett. 2007;248(1):68‐80.
Ortenberg R, Sapoznik S, Zippel D, et al. Serum CEACAM1 elevation correlates with melanoma progression and failure to respond to adoptive cell transfer immunotherapy. J Immunol Res. 2015;2015:902137.
Sivan S, Suzan F, Rona O, et al. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol. 2012;2012:290536.
Khatib N, Pe'er J, Ortenberg R, et al. Carcinoembryonic antigen cell adhesion molecule‐1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers. Invest Ophthalmol Vis Sci. 2011;52(13):9368‐9372.
Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Investig Surg. 2023;36(1):2129884.
Gong DY, Fu HX, Peng Y, You YQ, Li ZP. Diagnostic value of serum CEACAM1 in patients with pancreatic cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31(1):164‐166.
Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas. 2007;34(4):436‐443.
Zinczuk J, Zareba K, Romaniuk W, et al. Expression of chosen carcinoembryonic‐related cell adhesion molecules in pancreatic intraepithelial neoplasia (PanIN) associated with chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC). Int J Med Sci. 2019;16(4):583‐592.
Gebauer F, Wicklein D, Horst J, et al. Carcinoembryonic antigen‐related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. PLoS One. 2014;9(11):e113023.
Giulietti M, Occhipinti G, Principato G, Piva F. Weighted gene co‐expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development. Cell Oncol (Dordr). 2016;39(4):379‐388.
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.
Cruz PV, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K. Loss of carcinoembryonic antigen‐related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma. Cancer. 2005;104(2):354‐360.
Kiriyama S, Yokoyama S, Ueno M, et al. CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma. Ann Surg Oncol. 2014;21:S505‐S514.
Zhu J, Yang Y, Ma C, Zhang G, Wang K, Hu S. CEACAM1 cytoplastic expression is closely related to tumor angiogenesis and poorer relapse‐free survival after curative resection of hepatocellular carcinoma. World J Surg. 2011;35(10):2259‐2265.
Koniger V, Holsten L, Harrison U, et al. Helicobacter pylori exploits human CEACAMs via HopQ for adherence and translocation of CagA. Nat Microbiol. 2016;2:16188.
Guo JQ, Yu WH, Wang HJ, et al. Different expression patterns of CEACAM1 and its impacts on angiogenesis in gastric nonneoplastic and neoplastic lesions. Ann Surg Oncol. 2012;19(Suppl 3):S365‐S374.
Shi JF, Xu SX, He P, Xi ZH. Expression of carcinoembryonic antigen‐related cell adhesion molecule 1(CEACAM1) and its correlation with angiogenesis in gastric cancer. Pathol Res Pract. 2014;210(8):473‐476.
Zhou M, Jin Z, Liu Y, et al. Up‐regulation of carcinoembryonic antigen‐related cell adhesion molecule 1 in gastrointestinal cancer and its clinical relevance. Acta Biochim Biophys Sin Shanghai. 2017;49(8):737‐743.
Takeuchi A, Yokoyama S, Nakamori M, et al. Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer. Sci Rep. 2019;9(1):12702.
Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019;99(3):179‐184.
Di Meo A, Batruch I, Brown MD, et al. Searching for prognostic biomarkers for small renal masses in the urinary proteome. Int J Cancer. 2020;146(8):2315‐2325.
Kang ZP, Wang LX, Liu J, Ouyang H, Xie S, Tan Y. Expression of CEACAM1 and CD105 in renal cell carcinoma and its correlation with microvessel density. Crit Rev Eukaryot Gene Expr. 2021;31(1):1‐9.
Yang L, Liu Y, Zhang B, et al. CEACAM1 is a prognostic biomarker and correlated with immune cell infiltration in clear cell renal cell carcinoma. Dis Markers. 2023;2023:3606362.
Phan D, Sui X, Chen DT, Najjar SM, Jenster G, Lin SH. Androgen regulation of the cell‐cell adhesion molecule‐1 (Ceacam1) gene. Mol Cell Endocrinol. 2001;184(1–2):115‐123.
Hsieh JT, Luo W, Song W, et al. Tumor suppressive role of an androgen‐regulated epithelial cell adhesion molecule (C‐CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res. 1995;55(1):190‐197.
Lin SH, Pu YS. Function and therapeutic implication of C‐CAM cell‐adhesion molecule in prostate cancer. Semin Oncol. 1999;26(2):227‐233.
Busch C, Hanssen TA, Wagener C, OBrink B. Down‐regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum Pathol. 2002;33(3):290‐298.
Luebke AM, Ricken W, Kluth M, et al. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion‐positive prostate cancers. Int J Cancer. 2020;147(2):575‐583.
Tilki D, Irmak S, Oliveira‐Ferrer L, et al. CEA‐related cell adhesion molecule‐1 is involved in angiogenic switch in prostate cancer. Oncogene. 2006;25(36):4965‐4974.
Liu J, Ramakrishnan SK, Khuder SS, et al. High‐calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor gene. Mol Metab. 2015;4(3):186‐198.
Liu J, Muturi HT, Khuder SS, et al. Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. Metabolism. 2020;107:154215.
McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin‐embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999;59(17):4291‐4296.
Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. 2003;28(2):145‐153.
Chen M, Zhang J, Sampieri K, et al. An aberrant SREBP‐dependent lipogenic program promotes metastatic prostate cancer. Nat Genet. 2018;50(2):206‐218.
Lucarini G, Zizzi A, Re M, Sayeed MA, Di Primio R, Rubini C. Prognostic implication of CEACAM1 expression in squamous cell carcinoma of the larynx: pilot study. Head Neck. 2019;41(6):1615‐1621.
Yang F, Zeng Z, Li J, Ren X, Wei F. TIM‐3 and CEACAM1 are prognostic factors in head and neck squamous cell carcinoma. Front Mol Biosci. 2021;8:619765.
Qian W, Huang P, Liang X, Chen Y, Guan B. High expression of carcinoembryonic antigen‐associated cell adhesion molecule 1 is associated with microangiogenesis in esophageal squamous cell carcinoma. Transl Cancer Res. 2020;9(8):4762‐4769.
Albarran‐Somoza B, Franco‐Topete R, Delgado‐Rizo V, et al. CEACAM1 in cervical cancer and precursor lesions: association with human papillomavirus infection. J Histochem Cytochem. 2006;54(12):1393‐1399.
Igami K, Uchiumi T, Shiota M, et al. Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients. Cancer Sci. 2022;113(9):3120‐3133.
Oliveira‐Ferrer L, Tilki D, Ziegeler G, et al. Dual role of carcinoembryonic antigen‐related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res. 2004;64(24):8932‐8938.
Tilki D, Singer BB, Shariat SF, et al. CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol. 2010;57(4):648‐654.
Ueshima C, Kataoka TR, Takei Y, et al. CEACAM1 long isoform has opposite effects on the growth of human mastocytosis and medullary thyroid carcinoma cells. Cancer Med. 2017;6(4):845‐856.
Yu H, Yu J, Ren Y, Yang Y, Xiao X. Serum CEACAM1 level is associated with diagnosis and prognosis in patients with osteosarcoma. PLoS One. 2016;11(4):e0153601.
Oliveira‐Ferrer L, Goswami R, Galatenko V, et al. Prognostic impact of CEACAM1 in node‐negative ovarian cancer patients. Dis Markers. 2018;2018:6714287.
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374‐403.
Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52(1):55‐81.
Chen D, Iijima H, Nagaishi T, et al. Carcinoembryonic antigen‐related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function. J Immunol. 2004;172(6):3535‐3543.
Zhang Y, Cai P, Li L, et al. Co‐expression of TIM‐3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients. Int Immunopharmacol. 2017;43:210‐218.
Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM‐3‐mediated tolerance and exhaustion. Nature. 2015;517(7534):386‐390.
Markel G, Lieberman N, Katz G, et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC‐independent inhibitory mechanism of cytotoxicity. J Immunol. 2002;168(6):2803‐2810.
Hosomi S, Chen Z, Baker K, et al. CEACAM1 on activated NK cells inhibits NKG2D‐mediated cytolytic function and signaling. Eur J Immunol. 2013;43(9):2473‐2483.
Chen Z, Chen L, Baker K, et al. CEACAM1 dampens antitumor immunity by down‐regulating NKG2D ligand expression on tumor cells. J Exp Med. 2011;208(13):2633‐2640.
Park DJ, Sung PS, Kim JH, et al. EpCAM‐high liver cancer stem cells resist natural killer cell‐mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer. 2020;8(1):e000301.
Huang YH, Yoon CH, Gandhi A, et al. High‐dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance. Commun Med (Lond). 2024;4(1):128.
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27‐41.
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361‐371.
Montfort A, Colacios C, Levade T, Andrieu‐Abadie N, Meyer N, Segui B. The TNF paradox in cancer progression and immunotherapy. Front Immunol. 2019;10:1818.
Renz PF, Ghoshdastider U, Baghai Sain S, et al. In vivo single‐cell CRISPR uncovers distinct TNF programmes in tumour evolution. Nature. 2024;632(8024):419‐428.
Ghavampour S, Kleefeldt F, Bommel H, et al. Endothelial barrier function is differentially regulated by CEACAM1‐mediated signaling. FASEB J. 2018;32(10):5612‐5625.
Kleefeldt F, Bommel H, Broede B, et al. Aging‐related carcinoembryonic antigen‐related cell adhesion molecule 1 signaling promotes vascular dysfunction. Aging Cell. 2019;18(6):e13025.
Götz L, Rueckschloss U, Reimer A, et al. Vascular inflammaging: Endothelial CEACAM1 expression is upregulated by TNF‐α via independent activation of NF‐κB and β‐catenin signaling. Aging Cell. 2024;e14384. https://doi.org/10.1111/acel.14384
Cao Y, Arbiser J, D'Amato RJ, et al. Forty‐year journey of angiogenesis translational research. Sci Transl Med. 2011;3(114):114rv113.
Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745‐1770.
Ergun S, Kilik N, Ziegeler G, et al. CEA‐related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell. 2000;5(2):311‐320.
Gerstel D, Wegwitz F, Jannasch K, et al. CEACAM1 creates a pro‐angiogenic tumor microenvironment that supports tumor vessel maturation. Oncogene. 2011;30(41):4275‐4288.
Nouvion AL, Oubaha M, Leblanc S, et al. CEACAM1: a key regulator of vascular permeability. J Cell Sci. 2010;123(Pt 24):4221‐4230.
Kilic N, Oliveira‐Ferrer L, Neshat‐Vahid S, et al. Lymphatic reprogramming of microvascular endothelial cells by CEA‐related cell adhesion molecule‐1 via interaction with VEGFR‐3 and Prox1. Blood. 2007;110(13):4223‐4233.
Zaffran I, Landolina N, Gaur P, et al. Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. Cancer Gene Ther. 2022;29(11):1676‐1685.
Dupuis ML, Fiori V, Soriani A, et al. The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitro. J Immunother. 2015;38(9):357‐370.
Centonze M, Fiori V, Kujawski M, et al. Development and characterization of DIA 12.3, a fully human intact anti‐CEACAM1 monoclonal antibody. PLoS One. 2024;19(2):e0295345.
Ben‐Moshe T, Sapir Y, Mandel I, Hakim M, Hashmueli S, Markel G. Inhibition of the novel immune checkpoint CEACAM1 enhances anti‐tumor activity. Ann Oncol. 2015;26:ii23.
Markel G, Sapir Y, Mandel I, et al. Inhibition of the novel immune checkpoint CEACAM1 to enhance anti‐tumor immunological activity. J Clin Oncol. 2016;34:3044.
Borazanci E, Al Hallak MN, Eder JP, et al. 1027TiP a phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab‐paclitaxel in pancreatic cancer. Ann Oncol. 2021;32:S861.
Shapira R, Weber JS, Geva R, et al. A phase I, open‐label, multicenter, single‐dose escalation and multi‐dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies. J Clin Oncol. 2020;38:3094.
Hollandsworth HM, Amirfakhri S, Filemoni F, et al. Anti‐carcinoembryonic antigen‐related cell adhesion molecule antibody for fluorescence visualization of primary colon cancer and metastases in patient‐derived orthotopic xenograft mouse models. Oncotarget. 2020;11(4):429‐439.